Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Search
About Us
Sign in
Chemical Industry News, Data & Insights
About Us
Sign in
Home
News
Topics
Sectors
Reports
Events
Clusters
Products
WEEKLY
FOCUS
ALPHA
Products
WEEKLY
FOCUS
ALPHA
Regulatory and Compliance Updates news
(page 7)
26 May 2026
AkzoNobel supplies coatings for Songyuan green energy park
Songyuan phase-2 park runs on 100% renewables, targeting 45,000 t/yr green H2 and 200,000 t/yr green ammonia/methanol; protective systems reduce VOCs and guard assets from corrosion, CUI and heat.
26 May 2026
Lilly acquires three companies to expand infectious disease portfolio
Adds a better-tolerated shingles vaccine, bacterial-toxin vaccine platform for S. aureus, N. gonorrhoeae and C. trachomatis, and nanoparticle EBV vaccine tech; deals include milestone payments.
26 May 2026
X-Press Feeders completes Rotterdam’s first ethanol bunkering
Eco Levant received separate ISCC-certified loads: 90% biomethanol and 10% second-gen ethanol. Delivered by one inland bunker vessel, blended onboard. Shows fuel flexibility and CO2-reduction potential.
26 May 2026
LKAB granted permit for Luleå critical‑minerals industrial park
Plan enables extraction of phosphorus and all 17 rare earths from iron‑ore residues; demo plant nearing operation; supports EU supply security, regional jobs; full investment pending tests.
26 May 2026
AGC Biologics Starts NN4101 Bispecific Antibody Development and GMP Production
With Novelty Nobility, moves Copenhagen cell‑line/MCB work to GMP manufacturing in Chiba from May 2026. Targets retinal neovascular disease; global cGMP network enables tech transfer.
25 May 2026
Lilly's VERVE-102 single infusion durably lowers PCSK9 up to 88% and LDL-C up to 62%
Phase 1b Heart-2: single IV base-editing dose gave dose-dependent, durable PCSK9/LDL-C reductions up to 18 months in HeFH/premature CAD; well tolerated; FDA Fast Track; Phase 2 planned.
The right choices in the European chemical industry
Save time with
chemXplore Alpha
Learn more
25 May 2026
PETRONAS: Lifeboat-maintenance incident at FSO Sepat kills three
FSO Sepat lifeboat-maintenance incident involved four contractor personnel; one injured and evacuated for treatment. Investigations ongoing; company offering support and condolences.
23 May 2026
MOL opens probe into Olefin-1 incident at Tiszaújváros
Cooperating with authorities; unit draining underway for damage assessment. Two discharged, seven hospitalized (stable). Psychological support provided. Fuel supply unaffected; other units operating.
22 May 2026
Boehringer Ingelheim: CHMP backs JASCAYD (nerandomilast) for IPF and PPF
CHMP recommends EU approval after Phase III FIBRONEER trials showed slowed FVC decline in IPF and PPF; oral preferential PDE4B inhibitor already authorised in multiple countries.
22 May 2026
MOL Petrochemicals explosion in Tiszaújváros — one dead, several injured
Fire at olefin plant is being extinguished; company cooperating with authorities. CEO en route. Company expresses condolences and regards the colleague as part of the corporate group.
22 May 2026
MOL obtains U.S. license to continue NIS negotiations
OFAC granted a license to continue negotiations to acquire a majority stake in NIS until 6 June 2026; talks enter final phase—significant progress, but some terms remain to be settled.
22 May 2026
MOL Olefin-1 explosion in Tiszaújváros
Explosion during unit restart left one worker dead and nine injured; fire extinguished. Investigation under way. Other complex units keep running; refining and fuel supply unaffected; event insured.
22 May 2026
Eli Lilly's Foundayo (orforglipron) reduces body weight up to 13% in adults 65+
Once-daily oral orforglipron can be taken any time without food/water restrictions; showed significant 72-week weight loss across ages and diabetes status; safety consistent; GI AEs common.
22 May 2026
Merck secures CHMP positive opinion for KEYTRUDA + Padcev in cisplatin‑ineligible resectable MIBC
CHMP backed perioperative regimen for cisplatin‑ineligible resectable MIBC after Phase 3 KEYNOTE‑905 showed significant EFS, OS and pCR gains; EC decision due by Q3 2026; FDA cleared Nov 2025.
22 May 2026
Novo Nordisk: CHMP recommends Wegovy pill (oral semaglutide), the first oral GLP‑1, for EU approval
Oral semaglutide showed 16.6% mean weight loss (OASIS4, adherent); SELECT data added to label for CV risk reduction; no drug-drug restrictions; planned launch outside US H2 2026.
22 May 2026
Port of Rotterdam demonstrates safe ship-to-ship ammonia bunkering (MAGPIE)
Full-scale ship-to-ship ammonia bunkering demo found bunkering can be done safely in active ports if planned with robust safety, equipment and regulatory frameworks; report gives practical guidance.
21 May 2026
Rely wins Power2X EPC for 20MW Djewels green hydrogen plant in Delfzijl
Project reached FID/NTP and moves into construction. Will use John Cockerill pressurized alkaline electrolysis; first hydrogen expected mid‑2028; plant ties into local Chemical Park and Nobian.
21 May 2026
PureCycle and Reliable Caps launch closures made with PureFive recycled polypropylene (up to 75% PCR)
Bright white, colorable closures using certified, domestically sourced recycled PP; FDA-grade and GreenCircle‑certified, suited for contact‑sensitive food, beverage and personal‑care packaging.
21 May 2026
Hycamite plans 200 kt/yr graphite plant in Finland
EU CRMA status and new tech enable a phased Finnish project: Phase 1 demo starts next year; full scale could reach 200 kt/yr (~40% of EU battery graphite demand), serving batteries and industry.
20 May 2026
BASF and Cromology convert end‑of‑life tires into binder for Tollens Maxiline+ wall paint
Chemically recycled styrene-acrylate binder from tire pyrolysis oil used in interior wall paint via mass-balance. REDcert² certified; 10 L ≈ 2 tires; reduces fossil feedstock and CO₂.
19 May 2026
European Commission unveils Fertiliser Action Plan to secure EU fertiliser supply and food security
Immediate liquidity relief and CAP flexibility for farmers; boost domestic, low‑carbon and circular production; improve market transparency, monitoring, and preparedness.
19 May 2026
Statkraft to invest NOK 80bn in Norwegian hydropower over 10 years
Half for major maintenance; rest for upgrades, new capacity and wind repowering. Nationwide dam reinforcements, turbine and tunnel refurbishments; projects need permits and profitability
18 May 2026
Boehringer Ingelheim's JASCAYD (nerandomilast) approved in Japan for IPF and PPF
First oral PDE4B inhibitor shows slowed FVC decline in FIBRONEER Phase III; pooled analysis showed 59% nominal death reduction. Common AE: diarrhea; EU/UK reviews ongoing.
18 May 2026
Genentech to present ASCO 2026 data on giredestrant in early ER+ breast cancer
Presents data on nine drugs across 15+ indications: breast‑cancer first‑line/post‑progression analyses, HER2 brain‑penetrant TKI, KRAS G12C+pembrolizumab, and lymphoma ADC/bispecific combo
18 May 2026
NRC Issues FONSI for Dow and X-energy Long Mott Nuclear Project in Texas
NRC completed an Environmental Assessment and issued a FONSI for a proposed advanced SMR at Seadrift, Texas, clearing a key Construction Permit step to supply electricity and industrial steam.
18 May 2026
Essar Energy Transition completes Pre‑FEED for Stanlow Methanol‑to‑Jet SAF hub
Planned plant will convert ~550,000 tpa renewable methanol into >200,000 tpa jet fuel, using existing refinery blending and pipeline export; FEED this year, FID by early 2028.
18 May 2026
Chugai’s Alecensa Gets World-First Tumor‑Agnostic Approval for ALK‑Positive Solid Tumors
Japan approves tumor‑agnostic ALK inhibitor for ALK‑fusion solid tumors including pediatrics. TACKLE Phase II showed 70–76% response in ALK‑fusion cases; safety consistent. FoundationOne CDx approved.
18 May 2026
Chugai: MHLW approves FoundationOne CDx as Alecensa companion diagnostic for ALK‑positive solid tumors
TACKLE Phase II supported Alecensa's efficacy/safety, enabling a partial marketing-authorization change; FoundationOne CDx expands tumor-agnostic genomic profiling and treatment options.
18 May 2026
GSK’s Arexvy gains expanded approval in Japan for at‑risk adults 18–59
Approval now explicitly includes immunocompromised adults; Phase IIIb showed non‑inferior immune response versus older adults and a safety profile consistent with prior trials.
15 May 2026
Genentech’s Tecentriq approved by FDA as ctDNA‑guided adjuvant therapy for MIBC
FDA approves first ctDNA‑MRD‑guided adjuvant option for muscle‑invasive bladder cancer. IMvigor011: ctDNA+ patients had 36% reduced DFS risk and 41% reduced OS risk; Signatera CDx authorized.
← Previous
Next →
